- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04590326
Studie zu REGN5668 in Kombination mit Cemiplimab oder REGN4018 bei erwachsenen Frauen mit wiederkehrendem Eierstockkrebs
Phase-1/2-Studie zu REGN5668 (MUC16xCD28, ein kostimulatorisches Bispezifikum), verabreicht in Kombination mit Cemiplimab oder REGN4018 (MUC16xCD3)
This study is researching an investigational drug called REGN5668 :
- alone or,
- combined with cemiplimab (also known as REGN2810) or,
- combined with both cemiplimab and fianlimab (also known as REGN3767), or
- combined with ubamatamab (also known as REGN4018), with or without sarilumab.
The main purposes of this study are to:
- Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
- Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus
This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.
The study is looking at several other research questions, including:
- Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
- To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer
Studienübersicht
Status
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-Mail: clinicaltrials@regeneron.com
Studienorte
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgien, 3000
- Rekrutierung
- Universitair Ziekenhuis Leuven
-
-
-
-
-
São Paulo, Brasilien, 01509-010
- Rekrutierung
- AC Camargo Cancer Center, Fundacao Antonio Prudente
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90619-900
- Rekrutierung
- Centro de Pesquisa em Oncologia PUCRS
-
-
São Paulo
-
Barretos, São Paulo, Brasilien, 14784-400
- Rekrutierung
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
Sorocaba, São Paulo, Brasilien, 18065-100
- Rekrutierung
- Unimed Sorocaba
-
-
-
-
-
Villejuif, Frankreich, 94805
- Rekrutierung
- Institut Gustave Roussy
-
-
Auvergne-Rhône
-
Pierre-Bénite, Auvergne-Rhône, Frankreich, 69310
- Rekrutierung
- Hopital Lyon Sud
-
-
Bourgogne-Franche-Comté
-
Dijon, Bourgogne-Franche-Comté, Frankreich, 21000
- Rekrutierung
- Centre Georges Francois Leclerc
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Frankreich, 33076
- Rekrutierung
- Institut Bergonie
-
-
Normandy
-
Caen, Normandy, Frankreich, 14076
- Rekrutierung
- Centre Francois Baclesse (CFB)
-
-
-
-
-
Girona, Spanien, 17007
- Rekrutierung
- Institut Catala dOncologia Girona
-
Madrid, Spanien, 28040
- Rekrutierung
- Hospital Universitario Fundacion Jimenez
-
Madrid, Spanien, 28040
- Rekrutierung
- Ciudad Universitaria
-
Madrid, Spanien, 28041
- Rekrutierung
- Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
-
-
A Coruna
-
Santiago de Compostela, A Coruna, Spanien, 15706
- Rekrutierung
- Hospital Clinico Universitario Santiago de Compostela
-
-
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- Rekrutierung
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Vereinigte Staaten, 92618
- Rekrutierung
- The City of Hope Orange County Lennar Foundation Cancer Center
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- Chao Family Comprehensive Cancer Center
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- Abgeschlossen
- H. Lee Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Rekrutierung
- Massachusetts General Hospital
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Dana Farber Cancer Institute Brookline Avenue
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Rekrutierung
- Karmanos Cancer Institute
-
-
New York
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- Perelman School of Medicine at the University of Pennsylvania
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- Rekrutierung
- Seattle Cancer Care Alliance at South Lake Union - G3630
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
- Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
- Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
- Has adequate organ and bone marrow function as defined in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has a life expectancy of at least 3 months
- Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol
Key Exclusion Criteria:
- Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
- Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
- Prior treatment with a Mucin 16 (MUC16)-targeted therapy
- Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
- Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
- Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
- Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
- Has history of clinically significant cardiovascular disease as defined in the protocol
- Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Module 1
REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab |
Administer per the protocol
Andere Namen:
Administer per the protocol
Andere Namen:
Administer per the protocol |
|
Experimental: Module 2
REGN5668 and ubamatamab |
Administer per the protocol
Andere Namen:
Administer per the protocol
Andere Namen:
Administer per the protocol
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLT)
Zeitfenster: 42 days
|
Dose escalation phase, Module 1 |
42 days
|
|
Incidence of DLTs
Zeitfenster: 21 days post combination administration
|
Dose escalation phase, Module 2 |
21 days post combination administration
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Zeitfenster: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of Serious Adverse Events (SAEs)
Zeitfenster: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of deaths
Zeitfenster: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
Zeitfenster: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
Zeitfenster: Through study completion, up to 5 years
|
Primary: Dose escalation phase |
Through study completion, up to 5 years
|
|
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Zeitfenster: Through study completion, up to 5 years
|
Primary: Dose expansion phase |
Through study completion, up to 5 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
ORR based on RECIST 1.1
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation phase |
Through study completion, up to 5 years
|
|
Best Overall Response (BOR) based on RECIST 1.1
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Duration Of Response (DOR) based on RECIST 1.1
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Disease Control Rate (DCR) based on RECIST 1.1
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Progression-Free Survival (PFS) based on RECIST 1.1
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against REGN5668
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against ubamatamab
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against cemiplimab
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against fianlimab
Zeitfenster: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Clinical Trial Management, Regeneron Pharmaceuticals
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des endokrinen Systems
- Pathologische Prozesse
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Krankheitsattribute
- Uteruserkrankungen
- Genitalerkrankungen, weiblich
- Neoplasmen der endokrinen Drüse
- Eierstockerkrankungen
- Adnexerkrankungen
- Genitale Neubildungen, weiblich
- Gonadenstörungen
- Uterusneoplasmen
- Eileitererkrankungen
- Pathologische Zustände, Anzeichen und Symptome
- Wiederauftreten
- Eierstocktumoren
- Endometriale Neubildungen
- Eileiterneoplasmen
- Cemiplimab
- Sarilumab
Andere Studien-ID-Nummern
- R5668-ONC-1938
- 2022-501904-83-00 (Ctis)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-Sharing-Zeitrahmen
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-Sharing-Zugriffskriterien
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- ANALYTIC_CODE
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .